Disease modification and other trials in systemic sclerosis have come a long way, but have to go further
Arthritis Care Res (Hoboken)
.
2012 Jul;64(7):955-9.
doi: 10.1002/acr.21673.
Authors
Janet E Pope
1
,
Dinesh Khanna
,
Sindhu R Johnson
,
Phil Clements
Affiliation
1
St. Joseph's Health Care London, University of Western Ontario, London, Ontario, Canada.
[email protected]
PMID:
22422634
DOI:
10.1002/acr.21673
No abstract available
Publication types
Research Support, Non-U.S. Gov't
Comment
MeSH terms
Antirheumatic Agents / therapeutic use*
Clinical Trials as Topic*
Humans
Randomized Controlled Trials as Topic*
Scleroderma, Systemic / drug therapy*
Substances
Antirheumatic Agents
Grants and funding
Canadian Institutes of Health Research/Canada